The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Jan 2015 08:30

RNS Number : 1404B
Midatech Pharma PLC
02 January 2015
 

 

For filings with the FSA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Midatech Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

x

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Woodford Investment Management LLP (Woodford)

4. Full name of shareholder(s)  (if different from 3.):iv

Clients of Woodford

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

29.12.14

6. Date on which issuer notified:

30.12.14

7. Threshold(s) that is/are crossed orreached: vi, vii

20%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00BRTL9B63

5,556,071

5,556,071

5,563,474

5,563,474

20%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

5,563,474

20%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Woodford Investment Management LLP as Investment Manager

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Jon Webb

15. Contact telephone number:

01865 809023

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBTMPTMBTMMRA
Date   Source Headline
10th Mar 20235:52 pmRNSFurther re: Notice of General Meeting
8th Mar 20237:00 amRNSPosting of Circular and Notice of General Meeting
17th Feb 20237:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSHolding(s) in Company
15th Feb 20232:49 pmRNSHolding(s) in Company
15th Feb 20231:36 pmRNSHolding(s) in Company
15th Feb 20231:26 pmRNSHolding(s) in Company
15th Feb 20238:05 amRNSClosing of $6.0m Private Placement & Broker Change
9th Feb 20235:10 pmRNSPrivate Placement Raising US$6.0 million
3rd Feb 20239:57 amRNSReceipt of NASDAQ Notice
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 202312:00 pmRNSResult of General Meeting
16th Jan 202311:24 amRNSHolding(s) in Company
12th Jan 20237:00 amRNSPlanned Dose Escalation in MTX-110 Phase 1 Study
6th Jan 20237:00 amRNSPosting of Circular and Notice of General Meeting
19th Dec 202212:06 pmRNSHolding(s) in Company
19th Dec 202210:48 amRNSHolding(s) in Company
19th Dec 20227:00 amRNSClosing of Offering, Revised Terms, AIM & Webinar
14th Dec 20222:05 pmRNSSecond Price Monitoring Extn
14th Dec 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 20223:22 pmRNSProposed Acquisition of Bioasis Technologies Inc
14th Nov 20227:00 amRNSFirst Patient Enrolled in Phase 1 Study of MTX-110
18th Oct 20227:00 amRNSReceipt of NASDAQ Notification
20th Sep 202211:51 amRNSHolding(s) in Company
14th Sep 20221:57 pmRNSADR Ratio Change
14th Sep 20227:00 amRNSInterim results for the six months to 30 June 2022
21st Jun 20227:00 amRNSMTX110 Development for the Treatment of Glioma
20th Jun 20225:58 pmRNSDirectorate Change
20th Jun 20222:33 pmRNSResult of 2022 Annual General Meeting
10th Jun 20227:00 amRNSRetirement of Chairman and Proposed New Chairman
10th Jun 20227:00 amRNSMTX110 Study to be Presented at ISPNO 2022
1st Jun 202212:23 pmRNSFast Track Designation for MTX110 Development
24th May 202211:09 amRNSPosting of Annual Report & Notice of AGM
27th Apr 20221:00 pmRNSIssue of Equity for Employee Share Incentive Plan
26th Apr 20227:00 amRNSResults for the Year Ended 31 December 2021
14th Apr 202212:37 pmRNSReceipt of NASDAQ Notice
17th Mar 20227:00 amRNSExercise of Warrants and Issue of Equity
9th Mar 20227:00 amRNSR&D collaboration with Janssen on second molecule
8th Mar 20229:30 amRNSAppointment of Nominated and Financial Adviser
9th Feb 20221:53 pmRNSHolding(s) in Company
18th Jan 20224:18 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSExtension of Janssen collaboration re Q-Sphera
7th Jan 20225:37 pmRNSHolding(s) in Company
13th Dec 20219:43 amRNSIND Application for MTX110 Study in GBM Effective
3rd Dec 20217:00 amRNSMidatech presenting at MelloMonday
24th Nov 20217:00 amRNSMidatech presenting at the Shares/AJ Bell Webinar
17th Sep 20219:31 amRNSInterim results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.